STAGE IVB PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVB PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test could tell doctors when to stop prostate cancer treatment early
Disease control Not yet recruitingThis study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to stop a targeted radiation therapy called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
Disease control Not yet recruitingThis phase 1 trial tests whether giving a higher first dose of the radioactive drug Lu-177-PSMA-617 can improve treatment for men with metastatic castration-resistant prostate cancer. The drug targets a protein on prostate cancer cells and delivers radiation to kill them. Researc…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Not yet recruitingThis phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radioactive drug aims to hit bone tumors while sparing marrow
Disease control Not yet recruitingThis early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Estrogen patch may ease hot flashes in prostate cancer treatment
Symptom relief Not yet recruitingThis study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC